Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korean And U.S. Presidents Welcome Long-Awaited Korea-U.S. FTA Ratification; Now Eyes on Seoul

This article was originally published in PharmAsia News

Executive Summary

SEOUL -Korean President Lee Myung-bak and U.S. President Barack Obama both welcomed and celebrated the U.S. Congress's ratification of the Free Trade Agreement, saying the historic free trade deal will benefit both countries. But ratification is still needed in South Korea, and political maneuvering by the country's ruling and opposition parties may delay the process

You may also be interested in...



Korea Ratifies Free Trade Agreement With U.S., Pleasing Pharma Industry

Patent linkage provisions among key benefits for the pharmaceutical industry.

Pharma Industry Applauds Final Push For Ratification Of Korea-U.S. FTA, Patent Linkage, Transparency, Among Benefits

SEOUL - South Korean Prime Minister Kim Hwang-sik called on cabinet ministers to ratify Korea's free trade agreement with the United States during the country's National Assembly session Oct. 4

Revised U.S.-Korea FTA Grants Three-year Grace Period To Korean Generic Drug Makers

SEOUL - Despite discontent among opposition parties in South Korea with the recently revised Free Trade Agreement with the U.S., Korea's generic drug makers are welcoming new supplementary agreements, which they say would give them a three-year grace period during which they could launch generic versions of patented products

Latest Headlines
See All
UsernamePublicRestriction

Register

SC076439

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel